Alignment of stakeholder agendas to facilitate the adoption of school-supervised asthma therapy
Lemon, Stephenie C
Gerald, Lynn B
AffiliationUniv Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Dept Hlth Promot Sci
MetadataShow full item record
CitationTrivedi, M, Patel, J, Hoque, S, et al. Alignment of stakeholder agendas to facilitate the adoption of school‐supervised asthma therapy. Pediatric Pulmonology. 2019; 1– 11. https://doi.org/10.1002/ppul.24611
Rights© 2019 Wiley Periodicals, Inc.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractBackground School-supervised inhaled corticosteroid (ICS) therapy improves pediatric asthma medication adherence, outcomes, and morbidity. However, school-supervised ICS therapy has not been widely adopted into practice. We developed Asthma Link (TM) as a sustainable, low-cost model of school-supervised asthma therapy, designed for real-world adoption. Initial outcomes of Asthma Link (TM) demonstrated a significant improvement in health outcomes. Objective In this study, we examined the perspectives of Asthma Link (TM) participants to identify systems-level barriers and facilitators to refine the Asthma Link (TM) protocol and facilitate real-world uptake of school-supervised asthma therapy. Methods Using qualitative research methods, we interviewed 29 participants in Asthma Link (TM) from 2016 to 2018. Semi-structured interviews were conducted over the phone. Interviews were transcribed and the transcripts were coded to identify major themes within and across stakeholder groups. Results Stakeholders agreed on many facilitators for successful Asthma Link (TM) execution including the brief and easy to follow procedures and the perceived beneficial health impacts for children involved. Some of the barriers identified were deviations from the protocol and insurance companies denying coverage for two inhalers. However, the participants did propose solutions to address these barriers. Conclusion Asthma Link (TM) is a low-cost, sustainable model of school-supervised asthma therapy that leverages the established infrastructure and collaboration of medical providers, school staff, and families. In this study, we elicited the perspectives from these stakeholder groups and identified an agreement in several facilitators, barriers, and proposed solutions that will ultimately inform refinement of the program protocol and support real-world adoption of Asthma Link (TM) and other similar models.
Note12 month embargo; published online: 19 December 2019
VersionFinal accepted manuscript
SponsorsNational Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [KL2TR001454, UL1TR001453-01, K24AI108622]
- School-based supervised therapy programs to improve asthma outcomes: current perspectives.
- Authors: Salazar G, Tarwala G, Reznik M
- Issue date: 2018
- Patients' perspective of barriers and facilitators to taking long-term controller medication for asthma: a novel taxonomy.
- Authors: Peláez S, Lamontagne AJ, Collin J, Gauthier A, Grad RM, Blais L, Lavoie KL, Bacon SL, Ernst P, Guay H, McKinney ML, Ducharme FM
- Issue date: 2015 Apr 25
- Barriers and Facilitators to Asthma Care After Hospitalization as Reported by Caregivers, Health Providers, and School Nurses.
- Authors: Parikh K, Paul J, Fousheé N, Waters D, Teach SJ, Hinds PS
- Issue date: 2018 Nov
- School-supervised use of a once-daily inhaled corticosteroid regimen: A cluster randomized trial.
- Authors: Gerald JK, Fisher JM, Brown MA, Clemens CJ, Moore MA, Carvajal SC, Bryson D, Stefan N, Billheimer D, Gerald LB
- Issue date: 2019 Feb
- Effect of the School-Based Telemedicine Enhanced Asthma Management (SB-TEAM) Program on Asthma Morbidity: A Randomized Clinical Trial.
- Authors: Halterman JS, Fagnano M, Tajon RS, Tremblay P, Wang H, Butz A, Perry TT, McConnochie KM
- Issue date: 2018 Mar 5